In summary, we demonstrated that blocking the ADM receptor inhibited proliferation of sunitinib-resistant RCC cells via the ERK/MAPK pathway, supporting the hypothesis that ADM can exert autocrine/paracrine effects promoting cancer growth in RCC. The gene discussed is ADM; the disease is cancer.